Connect with us

Guides

CannPal Announces Launch of Phase 2 Pilot Study of CBD-Derived Osteoarthritis Drug for Dogs

Jeanne Dininni

Published

on

CannPal Announces Launch of Phase 2 Pilot Study of CBD-Derived Osteoarthritis Drug for Dogs

CannPal Animal Therapeutics Limited issued a press release announcing that it has commenced a Phase 2A pilot dose determination study for CPAT-01, its lead drug candidate. The drug is being developed to control the development of pain and inflammation in dogs.

Phase 2 follows a successful Phase 1 research program. The first phase provided the company with a pre-clinical data pack for the drug candidate, which were 59 dogs. The pack included data on pharmacokinetics, gene expression, early dose-response, and inflammatory biomarkers. The company will file an INAD application with the FDA/CMV using the data pack.

The press release indicates that 60 dogs are expected to participate in the 8-week randomized double-blind placebo-controlled study, which will review the impact of CBD and THC in dogs diagnosed with arthritis. Enrolled in the study are 12 veterinary clinics in Australia. Aphria, a cannabis company, is supplying the trial material.

Layton Mills, the Founder and Managing Director of CannaPal, shared in the press release,

“I'm extremely pleased to commence our Phase 2 program for CPAT-01 with the start of our pilot dose determination study. This trial is a globally significant milestone, as it represents regulatory and development progress that is yet to be matched by an animal health Company developing cannabinoid-derived products for pets.”

Jeanne Dininni knows the wisdom of the writing industry and has locked arms with us to continue discovering and uncovering all things CBD and hemp. TOC welcomes her work as being humorous and entertaining on top of informative and authoritative.

Continue Reading

Disclaimer


Ultimate CBD Guide

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational purposes only.

Got news? Email contact@timesofcbd.com